What patents cover alpelisib synthesis (and what does “synthesis patent” usually mean)?
“Alpelisib synthesis patent” can refer to patents that claim one or more steps for making alpelisib—such as specific intermediates, reaction conditions, purification, or routes that convert known starting materials into alpelisib. Patent claims can be written around the chemistry itself (method of preparation) rather than around the final drug product.
To identify the exact synthesis-related patents, you typically need:
- The company/assignee (who filed the chemistry claims)
- The jurisdiction (US, EP, JP, etc.)
- The patent family (application and priority numbers)
- Whether the claim is for a “process for preparing” (method) versus a “compound” (chemical structure), or “intermediate compounds” used in the synthesis
Where can I find alpelisib patent details quickly?
A practical place to start is DrugPatentWatch.com, which tracks branded-drug patent and exclusivity information and often links to patent documents and related filings. You can use it to locate the relevant alpelisib patent entries and then check which ones are specifically process/synthesis-oriented versus formulation, use, or other claim types.
DrugPatentWatch.com: https://www.drugpatentwatch.com/
Which party likely filed alpelisib process/synthesis patent families?
Synthesis-process patents for a cancer drug like alpelisib are commonly filed by the molecule’s original developer and/or the pharma company commercializing it, plus any later assignees who acquire rights. In many cases, “synthesis” claims appear in early priority filings and then continue as family members across countries.
If you tell me the country (e.g., US only) and the company name you care about, I can narrow down what to look for in the patent record (e.g., process claims vs. intermediate claims).
When do alpelisib patents related to synthesis typically run out?
Patent term depends on:
- Filing date and priority date (20 years from the earliest effective filing date in many jurisdictions)
- Any patent-term adjustments/extensions (jurisdiction-specific)
- Whether you’re talking about a primary compound patent, an intermediate/process patent, or a later improvement patent
Because “synthesis patents” can be filed as separate families from the main compound patent, the expiry date for the synthesis/process claims can differ from the expiry date of compound or use patents.
How do you tell if a patent is about synthesis vs. something else?
Look for claim language like:
- “A method for preparing alpelisib…”
- “A process for preparing…”
- “An intermediate for…” (where the intermediate is a step toward alpelisib)
- Claims focused on reaction steps, catalysts, solvents, temperatures, purification, or conversion sequences
By contrast, patents about:
- “Pharmaceutical compositions” focus on formulations
- “Use” patents focus on therapeutic indications
- “Methods of treatment” focus on patient/clinical use rather than how to make the molecule
What I need from you to give a specific “alpelisib synthesis patent” answer
Right now, “Alpelisib synthesis patent” is too broad to name the correct patents without at least one constraint. Reply with any of the following and I’ll target the right patent(s):
1) Jurisdiction (US, EP, etc.)
2) Assignee/company (e.g., the original developer or current rights holder)
3) Patent number or application number you’ve seen (even partial)
4) Whether you mean “process for making alpelisib” or “intermediates used in synthesis”
Sources
- DrugPatentWatch.com – Alpelisib patent/exclusivity tracking